Condition: Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia · ph+ Acute Lymphoblastic Leukemia · Sponsor: University of Chicago
This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this study hope to learn if adding InO to standard induction treatment for Ph+ ALL will lead to quicker, complete molecular remission (where the disease is not detectable even with very sensitive testing techniques). The purpose of this research is to gather information regarding the effectiveness of InO in newly-diagnosed Ph+ ALL patients that have not yet received treatment.
This description comes directly from the study's public registry record.
Cancer Clinical Trials Office · 1-855-702-8222 · cancerclinicaltrials@bsd.uchicago.edu
Wendy Stock, MD · 773-834-8982 · PhaseIICRA@medicine.bsd.uchicago
Always discuss trial participation with your own doctor first.
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04747912